HOME >> MEDICINE >> NEWS
Baby and coated aspirin equally effective in thinning of blood when taken in combination with Plavix

Aspirin dose and type may not matter when taken in combination with Plavix for the purpose of thinning blood and possibly reducing the risk of stroke in people with cerebrovascular disease, according to research presented today at the American Stroke Association's 29th International Stroke Conference. The American Stroke Association is a division of the American Heart Association.

Northwestern Memorial researchers previously reported that the majority of patients who took baby or enteric-coated aspirin alone to prevent strokes were not getting the desired blood-thinning effects, causing concern among patients who chose to take coated or baby aspirin because of their reduced risk of gastrointestinal side effects.

"That's why we decided to study the efficacy of aspirin - in various doses and formulations - when taken in combination with Plavix," explains Mark J. Alberts, M.D., director of the stroke program at Northwestern Memorial Hospital and the study's lead author. "Plavix is a prescription antiplatelet medication that helps keep platelets in the blood from sticking together and forming clots. Plavix has fewer gastrointestinal side effects than adult-dose aspirin."

"While research has shown that the combined use of aspirin and Plavix provides an enhanced blood-thinning effect for patients trying to reduce their risk of vascular events, the optimal dose and formulation is unclear," according to Dr. Alberts. "This study is significant in that it continues to point researchers in the right direction - showing how we can maximize the effectiveness and safety of aspirin when used to reduce the risk of stroke."

Northwestern Memorial investigators collected data on aspirin dose, type (coated or uncoated), and demographic factors on a total of 69 in-patients and out-patients with cerebrovascular disease, including ischemic stroke and transient ischemic attacks (TIAs). Antiplatelet effects of aspirin were measured using a machine abo
'"/>

Contact: Patty Keiler
pkeiler@nmh.org
312-926-5900
Northwestern Memorial Hospital
5-Feb-2004


Page: 1 2

Related medicine news :

1. Loyola study shows drug-coated stent induces less inflammation than bare metal stent
2. Drug-coated stents effective in real world patients
3. The trojan clot-buster: Drug-coated red blood cells destroy blood clots from within
4. New study of coated stent long-term results disappointing
5. Silver-coated catheters cut infections & may save money, analysis finds
6. Many postmenopausal women with cardiovascular disease dont use lifesaving aspirin therapy
7. Survivors who stop taking aspirin increase risk of another stroke
8. Study says 43% of US adults at risk of heart disease are not utilizing aspirin therapy
9. Low-dose aspirin and stomach ulcer medications better for heart patients with GI complications
10. Statins and aspirin may protect against severe vision loss in elderly
11. One in five asthmatics are highly sensitive to aspirin

Post Your Comments:
(Date:4/24/2014)... from The University of Manchester have identified a way ... more open to treatment. , The study published today ... for the development of drugs to target cells that ... made the discovery whilst exploring the possible mechanisms behind ... treat breast and colon cancer. , Dr Andrew Gilmore, ...
(Date:4/24/2014)... with an antimicrobial peptide could help to lower the risk ... Optometry and Vision Science , official journal of the ... published by Lippincott Williams & Wilkins , a part ... and now humans support the biocompatibility and safety of lenses ... research by Debarun Dutta, B.Optom, of The University of New ...
(Date:4/24/2014)... new Institute for Biomedical Sciences at Georgia State ... grant to develop novel therapeutics against Respiratory Syncytial ... Eunice Kennedy Shriver National Institute Of Child Health ... Health will support Plemper,s drug development goals of ... distinct alternative compound. , Infections by RSV, a ...
(Date:4/24/2014)... than one out of three survivors of critical ... The Lancet Respiratory Medicine , and the ... than mentally. , It is one of the ... functional outcomes of critical care survivors, according to ... Medicine, and it highlights a significant public health ...
(Date:4/24/2014)... has found a relationship between motor skill deficiencies and ... in very young children. , The findings, believed ... relationship between motor skills and autism severity, indicate that ... included in treatment plans for young children with autism, ... of Public Health and Human Sciences. , "Recognizing ...
Breaking Medicine News(10 mins):Health News:Scientists find way to target cells resistant to chemo 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 2Health News:Study supports safety of antimicrobial peptide-coated contact lenses 3Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Motor skill deficiencies linked to autism severity in new research 2
(Date:1/15/2014)...  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ("Echo"), ... as a non-invasive, wireless continuous glucose monitoring system, today ... and Interim CEO of Echo Therapeutics, will present at ... Mr. Doman will make a corporate ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Drug Forecast and Market Analysis to 2022 ... PharmaPoint: Atopic Dermatitis - India Drug Forecast ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
Cached News: